Log In
Print
BCIQ
Print
Print this Print this
 

Xenopax

  Manage Alerts
Collapse Summary General Information
Company Shanghai CP Guojian Pharmaceutical Co. Ltd.
DescriptionHumanized mAb against interleukin-2 (IL-2) receptor alpha chain (CD25)
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationRenal transplant
Indication DetailsPrevent renal transplant rejection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today